Results 111 to 120 of about 20,935 (240)

Opioids and Cannabis: An Uncertain Combination? [PDF]

Anesthesiology
Boehnke KF.
europepmc   +1 more source

Psychiatric effects of cannabidiol, cannabinol, and tetrahydrocannabinol: A narrative review of clinical evidence and risk profiles

Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 3, September 2026.
Abstract Cannabinoid products are increasingly used worldwide despite limited psychiatric evidence. This narrative review synthesizes preclinical and clinical evidence on cannabidiol (CBD), cannabinol (CBN), and tetrahydrocannabinol (THC) to clarify their distinct psychiatric profiles and discuss how current evidence may inform ongoing clinical and ...
Yasuhiro Kishi, Ichiro Takumi, Kakusho Chigusa Nakajima‐Ohyama   +2 more
wiley   +1 more source

The detection of delta-9-tetrahydrocannabinol, delta-8-tetrahydrocannabinol, delta-10-tetrahydrocannabinol, and cannabidiol in hair specimens. [PDF]

J Anal Toxicol
Racines A, Jones J, Lea K, Coy D.
europepmc   +1 more source

Tetrahydrocannabinol [PDF]

, 2019
openaire   +1 more source

A MassQL‐Based Framework for Rule‐Guided MS/MS Class‐Level Retrieval and Analog Discovery of Cannabinoids

Rapid Communications in Mass Spectrometry, Volume 40, Issue 16, 30 August 2026.
ABSTRACT Rationale Cannabinoids comprise a chemically diverse group of meroterpenoids whose extensive isomerism, variable side‐chain length, and frequent oxidative or rearranged derivatives lead to strongly overlapping yet characteristic MS/MS fragmentation patterns. In untargeted LC–MS/MS datasets, this combination of structural diversity and spectral
Julia Maia Galvão de Queiroz, Fernanda Oliveira Chagas, Valdir Florêncio Veiga‐Júnior, Monica Costa Padilha, Ricardo M. Borges   +4 more
wiley   +1 more source

Investigation of the In Vitro and In Vivo Metabolism and μ‐Opioid Receptor Affinity of the Nitazene N‐Pyrrolidino Fluetonitazene

Drug Testing and Analysis, Volume 18, Issue 8, Page 1097-1113, August 2026.
Eight metabolites for N‐pyrrolidino fluetonitazene were identified in vitro, three of which (M2, M6 and M8) were present in an authentic urine sample. M2 was the most abundant in vivo metabolite and is a common marker metabolite of nitazepyne‐type substances.
Severin Zemp, Gaia Alluisetti, Wolfgang Weinmann, Bettina Schrag, Frank Sporkert, Maurine Leclerc, Katharina Elisabeth Grafinger   +6 more
wiley   +1 more source

Interpretive Reference Ranges for Plasma Drug Concentrations in Acute Recreational Drug Toxicity: A Short Communication. [PDF]

Ther Drug Monit
Boccuzzi S, Battal D, Cowan D, Dargan PI, Abbate V.   +4 more
europepmc   +1 more source

Exploring Cerumen as an Alternative Matrix for Drug Detection and Quantification: Method Development and Application in Clinical Samples

Drug Testing and Analysis, Volume 18, Issue 8, Page 1065-1075, August 2026.
An LC–MS/MS method was developed for the detection of 33 psychoactive medications in cerumen (earwax) and applied to the samples of 60 psychiatric inpatient volunteers. The findings highlighted the utility of cerumen as an innovative biospecimen in clinical toxicological analysis.
Dimitrios Phaedon Kevrekidis, Helen G. Gika, Georgios Panagiotoglou, Eleni Parlapani, Pavlos Pavlidis, Nikolaos Raikos   +5 more
wiley   +1 more source

Cannabinoids and opioid consumption in cancer pain: a systematic review and meta-analysis. [PDF]

Support Care Cancer
Creangă-Murariu I, Alexa-Stratulat T, Rusu MI, Chiru S, Dascalu C, Dobre CE, Tamba BI.   +6 more
europepmc   +1 more source

In Vitro Metabolism of Δ8‐, Δ9‐, and Δ10‐THC in Human Hepatocytes: Distinct Δ10‐THC Biotransformation and Implications for Drug Testing

Drug Testing and Analysis, Volume 18, Issue 8, Page 1114-1121, August 2026.
Δ8‐THC and Δ9‐THC showed comparable metabolic profiles. In contrast, Δ10‐THC underwent extensive glucuronidation and hydroxylation, with only minor formation of a carboxy metabolite, indicating a markedly different metabolic pathway. These differences may increase the risk of misidentification and misinterpretation in cannabis drug testing.
Robert Kronstrand, Henrik Green, Markus Loh, Fabian Rüttimann, Manuela Carla Monti   +4 more
wiley   +1 more source